Staff Profile | Faculty of Medical Sciences

Mike Cole

Statistician

Email: michael.cole@ncl.ac.uk
Telephone: +44 (0) 191 208 4587
Fax: +44 (0) 191 208 6043
Address: Population Health Sciences Institute
Newcastle University
4th Floor
Ridley Building 1
Queen Victoria Road
Newcastle upon Tyne
NE1 7RU
United Kingdom

Publications

Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson ADJ, Boddy AV. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clinical Cancer Research 2013, 19(2), 469-479.
Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, Aslam T, Patanwala I, Gaggar S, Cole M, Sumpter K, Stewart S, Rose J, Hudson M, Manas D, Reeves HL. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. Journal of Hepatology 2014, 60(1), 110-117.
Ryan SL, Schwalbe EC, Cole M, Lu Y, Lusher ME, Megahed H, O'Toole K, Nicholson SL, Bognar L, Garami M, Hauser P, Korshunov A, Pfister SM, Williamson D, Taylor RE, Ellison DW, Bailey S, Clifford SC. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathologica 2012, 123(4), 501-513.
Bomken S, Davies B, Chong L, Cole M, Wood KM, McDermott M, Tweddle DA. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival. Pediatric Hematology & Oncology 2011, 28(2), 106-114.
Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy. European Journal of Cancer 2011, 47(10), 1556-1563.
Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients. In: Pediatric Blood & Cancer: 43rd Congress of the International Society of Paediatric Oncology (SIOP). 2011, Auckland, New Zealand: John Wiley & Sons, Inc.
Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochemical Journal 2011, 436(3), 671–679.
Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC. Rapid Diagnosis of Medulloblastoma Molecular Subgroups. Clinical Cancer Research 2011, 17(7), 1883-1894.
Lindsey JC, Hill RM, Megahed H, Lusher ME, Schwalbe EC, Cole M, Hogg TL, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC. TP53 Mutations in Favorable-Risk Wnt/Wingless-Subtype Medulloblastomas. Journal of Clinical Oncology 2011, 29(12), E344-E346.
Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemotherapy and Pharmacology 2010, 66(4), 807-812.
Razak AA, Nutt J, O'Toole K, Black F, Cole M, Plummer R, Lunec J, Calvert H. Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy. In: EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin, Germany: Pergamon.
Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson ADJ. Glomerular Toxicity Persists 10 Years After Ifosfamide Treatment in Childhood and Is Not Predictable by Age or Dose. Pediatric Blood & Cancer 2010, 54(7), 983-989.
Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NV, Boos J, Kohler G, Leuschner I, Pearson ADJ, Lunec J, Tweddle DA. High frequency of p53/MDM2/p14^ARFpathway abnormalities in relapsed neuroblastoma. Clinical Cancer Research 2010, 16(4), 1108-1118.
Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British Journal of Cancer 2010, 102(6), 1003-1009.
Israels T, Damen CWN, Cole M, van Geloven N, Boddy AV, Caron HN, Beijnen JH, Molyneux EM, Veal GJ. Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. European Journal of Cancer 2010, 46(10), 1841-1847.
Rhodin M, Anderson B, Peters A, Coulthard M, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir M, Holford N. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatric Nephrology 2009, 24(1), 67-76.
Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson ADJ. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors. European Journal of Cancer 2009, 45(18), 3213-3219.
Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. British Journal of Cancer 2009, 101(2), 256-262.
Chinnaswamy G, Cole M, Boddy AV, Keir M, Price L, Parry AP, English M, Veal GJ. Estimation of renal function and its potential impact on carboplatin dosing in children with cancer. British Journal of Cancer 2008, 99(6), 894-899.
Matheson EC, Cole M, Wilkins BS, Hall AG. Mismatch repair defects in childhood acute lymphoblastic leukaemia at diagnosis and relapse. In: The British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium. 2008, Glasgow, UK: British Journal of Haematology: Wiley-Blackwell Publishing Ltd.
Cole M, Price L, Parry AP, Picton S, Waters F, Marshall S, Goran C, Parnham A, Wastell H, Reid M, Pearson ADJ, Boddy AV, Veal GJ. A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer. Pediatric Blood and Cancer 2007, 48(7), 687-695.
Chinnaswamy, G., Keir, M., Cole, M., Price, L., Parry, A., Boddy, A. V., Veal, G. J. Estimating glomerular filtration rate in children with cancer - Impact of methodology on carboplatin dosing. In: 39th Annual Conference of the International Society of Paediatric Oncology. 2007, National Centre for Performing Arts, Mumbai, India: Pediatric Blood and Cancer, Wiley-Liss, Inc.
Chen L, Malcolm AJ, Wood K, Cole M, Variend S, Cullinane C, Pearson ADJ, Lunec J, Tweddle DA. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007, 6(21), 2685-2696.
Lee JS, Verrill MW, Sludden J, Griffin MJ, Erb S, Sumpter KA, Cole M, Calvert AH, Boddy AV. Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer. Breast Cancer Research and Treatment 2007, 106(Supplement 1), S169 abstract 4011.
Chinnaswamy, G., Veal, G. J., Cole, M., Taylor, G. A., Errington, J. E., Gerrard, M., Boddy, A. V. Pharmacogenetics and metabolism of cyclophosphamide in paediatric cancer patients. In: 39th Annual Conference of the International Society of Paediatric Oncology. 2007, National Centre for Performing Arts, Mumbai, India: Pediatric Blood and Cancer, Wiley-Liss, Inc.
Veal GJ, Cole M, Errington J, Pearson ADJ, Foot A, Whyman G, Boddy AV. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group. British Journal of Cancer 2007, 96(3), 424-431.
Routledge DM, Jackson A, Bourn D, Bown NP, Cole M, Slatter MA, Gennery AR, Curtis A. Quantitative assessment of mixed chimerism in allogeneic stem cell transplant patients - A comparison of molecular genetic and cytogenetic approaches. Journal of Pediatric Hematology / Oncology 2007, 29(6), 428-431.
Cole M, Boddy AV, Kearns P, Teh KH, Price L, Parry A, Pearson ADJ, Veal GJ. Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?. Pediatric Blood and Cancer 2006, 46(7), 723-727.
Scott D, Straughton D, Cole M, Bailey S, Ellison DW, Clifford SC. Identification and analysis of tumor suppressor loci at chromosome 10q23.3-10q25.3 in medulloblastoma. Cell Cycle 2006, 5(20), 2381-2389.
Veal, G. J., Cole, M., Errington, J., Parry, A. P., Hale, J. P., Pearson, A. D. J., Howe, K., Chisholm, J., Beane, C., Brennan, B., Waters, F., Glaser, A., Hemsworth, S., McDowell, H., Wright, Y., Pritchard-Jones, K., Pinkerton, R., Jenner, G., Nicholson, J., Elsworth, A., Boddy, A. V. Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group study. Clinical Cancer Research 2005, 11(16), 5893-5899.
Cole M, Price L, Parry AP, Keir M, Pearson ADJ, Boddy A V, Veal GJ. Estimation of glomerular filtration rate in paediatric cancer patients using ⁵¹CR-EDTA population pharmacokinetics. British Journal of Cancer 2004, 90(1), 60-64.
McManamy CS, Lamont JM, Taylor RE, Cole M, Pearson ADJ, Clifford SC, Ellison DW. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. Journal of Neuropathology and Experimental Neurology 2003, 62(6), 627-632.
Thomas HD, Porter D, Bartelink I, Nobbs J, Cole M, Elliott S, Newell DR, Calvert AH, Highley M, Boddy AV. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. British Journal of Clinical Pharmacology 2002, 53(1), 83-91.
Burns, A.S.Y.W., Jaros, E., Cole, M., Perry, R., Pearson, A.D.J., Lunec, J. The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system. British Journal of Cancer 2002, 86(7), 1117-1123.
Levett DL, Middleton PG, Cole M, Reid MM. A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia. Medical and Pediatric Oncology 2001, 36(3), 365-371.
Connors S, Cuthbert G, Bown N, Cole M. Comparison of three BCR/ABL FISH probe systems for quantitative interphase analysis. In: Journal of Medical Genetics. 2001, BMJ Group.
Yule, SM, Price, L, Cole, M, Pearson, ADJ, Boddy, AV. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemotherapy and Pharmacology 2001, 47(3), 222-228.
Tweddle, D. A., Pinkerton, C. R., Lewis, I. J., Ellershaw, C., Cole, M., Pearson, A. D. J. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Medical and Pediatric Oncology 2001, 36(1), 239-242.
Tweddle, D. A., Malcolm, A. J., Cole, M., Pearson, A. D. J., Lunec, J. p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells. American Journal of Pathology 2001, 158(6), 2067-2077.
Yule, S. M., Price, L., Cole, M., Pearson, A. D. J., Boddy, A. V. Cyclophosphamide metabolism in children with Fanconi's anaemia. Bone Marrow Transplantation 1999, 24(2), 123-128.
Yule, S. M., Walker, D., Cole, M., McSorley, L., Cholerton, S., Daly, A. K., Pearson, A. D. J., Boddy, A. V. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metabolism and Disposition 1999, 27(3), 417-421.
Lowis SP, Price L, Pearson ADJ, Newell DR, Cole M. A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. British Journal of Cancer 1998, 77(12), 2318-2323.
Yule SM, Price L, Cole M, Pearson ADJ, Boddy AV. Cyclophosphamide metabolism in children with Fanconi's anaemia. British Journal of Haematology 1998, 101(Supplement 1), 92 A278.
Parker, L., Cole, M., Craft, A. W., Hey, E. Neonatal vitamin K administration and childhood cancer in the north of England: Retrospective case-control study. British Medical Journal 1998, 316(7126), 189-193.
Yule, S., Skinner, R., English, M. W., Cole, M., Pearson, A. D. J., Lucraft, H. H., Craft, A. W. Outcome and toxicity of an ifosfamide-based soft tissue sarcoma treatment protocol in children. The importance of local therapy. Sarcoma 1998, 2(3-4), 171-177.
Tweddle DA, Malcolm AJ, Reid MM, Cole M, Lunec J, Pearson ADJ. TP53 and related protein expression in primary and metastatic neuroblastoma. British Journal of Cancer 1998, 78(Suppl. 1), 19-19.
Yule, S., Boddy, A. V., Cole, M., Price, L., Wyllie, R., Tasso, M., Pearson, A. D. J., Idle, J. Cyclophosphamide pharmacokinetics in children. British Journal of Clinical Pharmacology 1996, 41(1), 13-19.
Skinner, R., Cole, M., Pearson, A. D. J., Coulthard, M. G., Craft, A. W. Specificity of pH and osmolality of early morning urine sample in assessing distal renal tubular function in children: Results in healthy children. British Medical Journal - Clinical Research Edition 1996, 312(7042), 1337-1338.
Peng, B., Boddy, A. V., Cole, M., Pearson, A. D. J., Chatelut, E., Rubie, H., Newell, D. R.
Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients
. European Journal of Cancer 1995, 31(11), 1804-1810.
Yule, S. M., Boddy, A. V., Cole, M., Price, L., Wyllie, R., Tasso, M. J., Pearson, A. D. J., Idle, J. R. Cyclophosphamide Metabolism in Children. Cancer Research 1995, 55(4), 803-809.
Craft, A. W., Parker, L., Stiller, C., Cole, M. Screening for wilms' tumor in patients with aniridia, Beckwith syndrome, or hemihypertrophy. Medical and Pediatric Oncology 1995, 24(4), 231-234.
Boddy, A. V., Cole, M., Pearson, A. D. J., Idle, J. R. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemotherapy and Pharmacology 1995, 36(1), 53-60.
Cole M, Craft AW, Parker L, Bell S, Seviour JA, McGill AC, Dale G. Urinary creatinine adjusted reference ranges for homovanillic and vanillylmandelic acid in children and adults. Clinica Chimica Acta 1995, 236(1), 19-32.
Hall AG, Autzen P, Cattan AR, Malcolm AJ, Cole M, Kernahan J, Reid MM. Expression of mu class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia. Cancer Research 1994, 54(20), 5251-5254.
Bell S, Parker L, Craft AW, Dale G, McGill AC, Seviour J, Cole M, Smith J. False positive results in a neuroblastoma screening programme. Medical and Pediatric Oncology 1994, 22(3), 181-186.
Skinner R, Cole M, Pearson ADJ, Keir MJ, Price L, Wyllie RA, Coulthard MG, Craft AW. Inaccuracy of glomerular-filtration rate estimation from height/plasma creatinine ratio. Archives of Disease in Childhood 1994, 70(5), 387-390.
Bell S, Parker L, Cole M, Craft AW. Screening infants for neuroblastoma: the parents' perspective. Pediatric Hematology and Oncology 1994, 11(4), 433-437.
Bell S, Parker L, Cole M, Craft AW. Screening infants for neuroblastoma: the parents perspective in false-positive cases. Pediatric Hematology and Oncology 1994, 11(2), 157-163.
Cole M, Parker L, Craft AW, Bell S, Dale G, McGill AC, Seviour JA, Smith J. Creatinine related reference ranges for urinary homovanillic-acid and vanillylmandelic acid at 6 months of age. Archives of Disease in Childhood 1993, 68(3), 376-378.
Lowis SP, Pearson ADJ, Newell DR, Cole M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Research 1993, 53(20), 4881-4889.
Craft, A. W., Parker, L., Dale, G., McGill, A. C., Seviour, J. A., Bell, S., Cole, M., Smith, J. A pilot study of screening for neuroblastoma in the north of England. American Journal of Pediatric Hematology / Oncology 1992, 14(4), 337-341.
Parker, L., Craft, A. W., Dale, G., Bell, S., Cole, M., McGill, A. C., Seviour, J. A., Smith, J. Screening for neuroblastoma in the north of England. British Medical Journal 1992, 305(6864), 1260-1263.
Seviour JA, McGill AC, Craft AW, Parker L, Bell S, Cole M, Smith J, Hawkins E, Brown J, Dale GA. Screening for neuroblastoma in the northern region of England: laboratory aspects. American Journal of Pediatric Hematology Oncology 1992, 14(4), 332-336.
Cole M, Hynes AM, Howel D, Hall L, Abinun M, Allahabadia A, Barrett T, Boelaert K, Drake AJ, Dimitri P, Kirk J, Zammitt N, Pearce S, Cheetham T. Adjuvant rituximab, a potential treatment for the young patient with Graves’ hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial. BMJ Open 2019, 9, e024705.
Parr JR, Todhunter E, Pennington L, Stocken D, Cadwgan J, O'Hare AE, Tuffrey C, Williams J, Cole M, Colver AF. Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Archives of of Disease in Childhood 2018, 103, 371-376.
Paleri V, Wood J, Patterson J, Stocken DD, Cole M, Vale L, Franks J, Guerrero-Urbano T, Donnelly R, Barclay S, Rapley T, Rousseau N. A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBE trial): study protocol. Pilot and feasibility studies 2016, 2(29).
Fordham SE, Cole M, Irving JA, Allan JM. Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia. Leukemia 2015, 29(2), 491-494.
Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patternson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia. Oncotarget 2015, 6(41), 43978-43991.
Fordham SE, Cole M, Irving JA, Allan JM. Cytarabine leaves a mutational fingerprint in relapsing leukemia. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
Jabber T, Cole M, Pickard S, Robson CN, Gnanapragasam VJ. Androgen deprivation therapy versus skeletal fractures. The effect of time dependent variables on observed risk. In: EUROPEAN UROLOGY SUPPLEMENTS. 2008, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS: ELSEVIER SCIENCE BV.
Cheetham TD, Cole M, Abinun M, Allahabadia A, Barratt T, Davies JH, Dimitri P, Drake A, Mohamed Z, Murray RD, Steele CA, Zammitt N, Carnell S, Prichard J, Watson G, Hambleton S, Matthews JNS, Pearce SHS. Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease. The Journal of clinical endocrinology and metabolism 2022, 107(3), 743-754.
Pratt AG, Siebert S, Cole M, Stocken DD, Yap C, Kelly S, Shaikh M, Cranston S, Morton M, Walker J, Frame S, Ng WF, Buckley CD, McInnes IB, Filer A, Isaacs JD. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. The Lancet Rheumatology 2021, 3(5), e337-e346.
Cole M, Yap C, Buckley C, Ng WF, McInnes I, Filer A, Siebert S, Pratt A, Isaacs JD, Stocken DD. TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis. Trials 2021, 22(1), 433.
Wood CL, Cole M, Donaldson M, Dunger DB, Wood R, Morrison N, Matthews JNS, Pearce SHS, Cheetham TD. Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis. European Journal of Endocrinology 2020, 183(6), 637-645.
Siebert S, Pratt AG, Stocken DD, Morton M, Cranston A, Cole M, Frame S, Buckley CD, Ng W-F, Filer A, McInnes IB, Isaacs JD. Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial. Medicine 2020, 99(26), e20458.